Mozobil(plerixafor)
Mozobil (plerixafor) is a small molecule pharmaceutical. Plerixafor was first approved as Mozobil on 2008-12-15. It is used to treat multiple myeloma and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, lymphoma, and multiple myeloma. The pharmaceutical is active against C-X-C chemokine receptor type 4. In addition, it is known to target C-C chemokine receptor type 4 and atypical chemokine receptor 3.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Mozobil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Plerixafor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MOZOBIL | Sanofi | N-022311 RX | 2008-12-15 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mozobil | New Drug Application | 2020-08-22 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2562 | Injection, plerixafor, 1 mg |
Clinical
Clinical Trials
147 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 14 | 12 | — | — | 2 | 21 | |
| Hodgkin disease | D006689 | C81 | 3 | 11 | — | — | 2 | 14 | |
| Myelodysplastic syndromes | D009190 | D46 | 5 | 7 | — | — | 1 | 11 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 6 | 5 | — | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 4 | 4 | — | — | 2 | 9 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | 5 | — | — | 2 | 8 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 3 | 4 | — | — | 1 | 7 | |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 4 | 4 | — | — | — | 5 |
| Healthy volunteers/patients | — | 3 | 2 | — | — | — | 5 | ||
| Glioblastoma | D005909 | EFO_0000515 | 3 | 3 | — | — | — | 4 |
Show 37 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Astrocytoma | D001254 | EFO_0000271 | 1 | — | — | — | — | 1 | |
| Oligodendroglioma | D009837 | EFO_0000631 | 1 | — | — | — | — | 1 | |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Osteosarcoma | D012516 | 1 | — | — | — | — | 1 | ||
| End stage liver disease | D058625 | EFO_1001311 | K72.1 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | J84.10 | 1 | — | — | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | — | — | — | 2 | 2 | |
| Hairy cell leukemia | D007943 | C91.4 | — | — | — | — | 2 | 2 | |
| Burkitt lymphoma | D002051 | C83.7 | — | — | — | — | 2 | 2 | |
| Large-cell lymphoma immunoblastic | D016400 | — | — | — | — | 2 | 2 | ||
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | — | — | — | — | 1 | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | — | — | — | 1 | 1 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | — | — | — | — | 1 | 1 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | — | — | — | — | 1 | 1 | |
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | — | — | — | — | 1 | 1 | |
| Large granular lymphocytic leukemia | D054066 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PLERIXAFOR |
| INN | plerixafor |
| Description | Plerixafor is an azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a role as an immunological adjuvant, an antineoplastic agent, an anti-HIV agent and a C-X-C chemokine receptor type 4 antagonist. It is an azamacrocycle, a crown amine, a secondary amino compound, an azacycloalkane, a tertiary amino compound and a member of benzenes. It is functionally related to a 1,4,8,11-tetraazacyclotetradecane. |
| Classification | Small molecule |
| Drug class | CXCR receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1 |
Identifiers
| PDB | — |
| CAS-ID | 110078-46-1 |
| RxCUI | 733003 |
| ChEMBL ID | CHEMBL18442 |
| ChEBI ID | — |
| PubChem CID | 65015 |
| DrugBank | DB06809 |
| UNII ID | S915P5499N (ChemIDplus, GSRS) |
Target
Agency Approved
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (P70658)
Alternate
CCR4
CCR4
ACKR3
ACKR3
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,515 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
122 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more